Kapelanski D P, Perelman M J, Faber L A, Paez D E, Rose E F, Behrendt D M
Department of Surgery, University of Iowa College of Medicine, Iowa City.
J Heart Transplant. 1990 Nov-Dec;9(6):668-73; discussion 673-4.
15-Deoxyspergualin is a synthetic polyamine that exhibits a novel spectrum of immunosuppressive activity in lower mammals. To define the clinical potential of this drug, we performed 25 abdominal heterotopic heart transplants in Macaca fasicularis. Donor and recipient pairs were selected from ABO-identical animals with negative erythrocyte crossmatches. All recipients received one dose of methylprednisolone sodium succinate at graft reperfusion. Five control recipients received no subsequent immunosuppression. Five recipients received high-dose 15-deoxyspergualin (7.5 mg/kg IM). Five recipients received low-dose 15-deoxyspergualin (2.0 mg/kg IM). Five recipients received cyclosporine (1.0 mg/kg IM). Five recipients received both 15-deoxyspergualin (2.0 mg/kg IM) and cyclosporine (1.0 mg/kg IM). Immunosuppressive agents were administered daily, beginning with the morning of operation, and were continued until the animal was killed or 30 days had elapsed. Graft function was assessed by daily palpation. Median graft survival among control recipients was 9 days (range, 6 to 34 days). At the dose used, cyclosporine alone did not influence either graft survival time (median survival, 13 days; range, 7 to 23 days) or rejection grade. Graft survival and rejection grade among recipients treated with low-dose 15-deoxyspergualin were not different from control recipients or those treated with cyclosporine alone (median survival, 10 days; range, 8 to 39 days). One recipient, killed on postoperative day 8, had an intraadominal abscess. In each of the recipients treated with high-dose 15-deoxyspergualin systemic toxicity developed, and the animal was killed when death appeared imminent, although graft contraction remained vigorous (median survival, 28 days; range 25 to 30 days).(ABSTRACT TRUNCATED AT 250 WORDS)
15-去氧精胍菌素是一种合成多胺,在低等哺乳动物中具有全新的免疫抑制活性谱。为了确定这种药物的临床潜力,我们在食蟹猴身上进行了25例腹部异位心脏移植。供体和受体对选自ABO血型相同且红细胞交叉配型阴性的动物。所有受体在移植物再灌注时接受一剂琥珀酸钠甲泼尼龙。五例对照受体未接受后续免疫抑制治疗。五例受体接受高剂量15-去氧精胍菌素(7.5毫克/千克,肌肉注射)。五例受体接受低剂量15-去氧精胍菌素(2.0毫克/千克,肌肉注射)。五例受体接受环孢素(1.0毫克/千克,肌肉注射)。五例受体接受15-去氧精胍菌素(2.0毫克/千克,肌肉注射)和环孢素(1.0毫克/千克,肌肉注射)联合治疗。免疫抑制剂从手术当天早晨开始每日给药,持续至动物处死或30天过去。通过每日触诊评估移植物功能。对照受体的移植物中位存活时间为9天(范围为6至34天)。在所使用的剂量下,单独使用环孢素既不影响移植物存活时间(中位存活时间为13天;范围为7至23天),也不影响排斥等级。接受低剂量15-去氧精胍菌素治疗的受体的移植物存活和排斥等级与对照受体或单独接受环孢素治疗的受体没有差异(中位存活时间为10天;范围为8至39天)。一名在术后第8天处死的受体患有腹腔内脓肿。在每例接受高剂量15-去氧精胍菌素治疗的受体中都出现了全身毒性,当死亡似乎即将发生时动物被处死,尽管移植物收缩仍然剧烈(中位存活时间为28天;范围为25至30天)。(摘要截取自250字)